Effect of Statins on Responses to Interferon Beta-1a

A retrospective study suggests that statins do not interfere with the therapeutic effects of IFNβ-1a in multiple sclerosis, but methodologic problems render the issue unresolved.

The quest for the holy grail of improved therapy for multiple sclerosis (MS) has led investigators to study the safety and efficacy of adding statins to either subcutaneous or intramuscular interferon beta (IFN-β). IFN-β is a standard-of-care injectable agent that reduces relapse rates and MRI activity. Statins, commonly used to lower cholesterol levels, can also modulate cellular immune responses in ways that may complement the effects of IFN-β. In a previous study (JW Neurol Feb 24 2009 and Neurology 2008; 71:1390), 26 patients with stable MS being treated with subcutaneous IFN-β-1a were randomized to receive either 40 mg or 80 mg of atorvastatin per day, or placebo, for 6 months. Surprisingly, 10 of 17 patients on IFN plus atorvastatin d…

Reviewing Author

Hillel Panitch, MD

Effect of Statins on Responses to Interferon Beta-1a

Topics

Reviewing Author